Inhalation of dimethyl fumarate-encapsulated solid lipid nanoparticles attenuate clinical signs of experimental autoimmune encephalomyelitis and pulmonary inflammatory dysfunction in mice
Authors:
Open Access
- 7 January 2022
- journal article
- research article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 136 (1) , 81-101
Abstract
Rationale: The FDA approved Dimethyl Fumarate (DMF) as an oral drug for Multiple Sclerosis treatment based on its immunomodulatory activities. However, it also caused severe adverse effects mainly related to the gastrointestinal system. Objective: Investigated the potential effects of solid lipid nanoparticles (SLN) containing DMF, administered by inhalation on the clinical signs, central nervous system (CNS) inflammatory response, and lung function changes in mice with experimental autoimmune encephalomyelitis (EAE). Materials and Methods: EAE was induced using MOG35-55 peptide in female C57BL/6J mice and were treated via inhalation with DMF-encapsulated SLN (CTRL/SLN/DMF and EAE/SLN/DMF), empty SLN (CTRL/SLN and EAE/SLN), or saline solution (CTRL/saline and EAE/saline), every 72 hours during 21 days. Results: After 21 days post-induction, EAE mice treated with DMF-loaded SLN, when compared to EAE/saline and EAE/SLN, showed decreased clinical score and weight loss, reduction in brain and spinal cord injury and inflammation, also related to the increased influx of Foxp3+ cells into the spinal cord and lung tissues. Moreover, our data revealed that EAE mice showed signs of respiratory disease, marked by increased vascular permeability, leukocyte influx, production of TNF-α and IL-17, perivascular and peribronchial inflammation, with pulmonary mechanical dysfunction associated with loss of respiratory volumes and elasticity, which DMF-encapsulated reverted in SLN nebulization. Conclusion: Our study suggests that inhalation of DMF-encapsulated SLN is an effective therapeutic protocol that reduces not only the CNS inflammatory process and disability progression, characteristic of EAE disease, but also protects mice from lung inflammation and pulmonary dysfunction.Keywords
This publication has 91 references indexed in Scilit:
- Anti-Inflammatory Dimethylfumarate: A Potential New Therapy for Asthma?Mediators of Inflammation, 2013
- T cells become licensed in the lung to enter the central nervous systemNature, 2012
- Asthmatic airway smooth muscle CXCL10 production: mitogen-activated protein kinase JNK involvementAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain, 2011
- Disruption of central nervous system barriers in multiple sclerosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- MP4- and MOG:35–55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum☆Journal of Neuroimmunology, 2007
- Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltrationClinical and Experimental Immunology, 2006
- CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis—an intravital microscopy studyJournal of Neuroimmunology, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic useBritish Journal of Dermatology, 1999